CN108689984A - A kind of biological synthesis method and its intermediate of ticagrelor intermediate - Google Patents
A kind of biological synthesis method and its intermediate of ticagrelor intermediate Download PDFInfo
- Publication number
- CN108689984A CN108689984A CN201810409842.0A CN201810409842A CN108689984A CN 108689984 A CN108689984 A CN 108689984A CN 201810409842 A CN201810409842 A CN 201810409842A CN 108689984 A CN108689984 A CN 108689984A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- anhydrous
- ticagrelor
- biological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a kind of biological synthesis method and its intermediate of ticagrelor intermediate, which is first made compound (3) by the oxidized reaction of compound (2);Compound (4) is obtained by the reaction through vicinal diols protection in the compound (3);Compound (5) is made through addition reaction with ethylene oxide in the compound (4);Ticagrelor midbody compound (1) is made through biological transformation in the compound (5), and reaction equation is as follows:
Description
Technical field
The invention belongs to technical field of medicine synthesis, and in particular to a kind of biological synthesis method of ticagrelor intermediate and
Wherein mesosome.
Background technology
Ticagrelor (common name:Ticagrelor, trade name BRILINTA), entitled (1S, 2S, 3R, the 5S) -3- of chemistry
[7-[(1R, 2S) -2- (3,4- difluorophenyls) cyclopropane An Jis ]- 5- (propane sulfydryl) -3H-[1,2,3]San Danzuo [4,5-d]
Bi Ding-3-Ji ]- 5- (2- hydroxyl ethanes oxygen) pentamethylene -1,2- glycol.The molecular weight of ticagrelor:522.57;CAS registration numbers:
274693-27-5;Structural formula is as follows:
Ticagrelor is researched and developed by AstraZeneca AB.A kind of platelet aggregation inhibitor of the FDA approvals of in September, 2015,
Ticagrelor is approved for the Antiplatelet therapy of ACS patient in the U.S..
Existing patented technology document:WO 2008018822A1 and WO 2008018823A1 etc. in the prior art, for closing
Often more complicated at the synthesis technology of the intermediate of ticagrelor, cost is higher, but also there are product yield is low and quality
The defect of difference, can not be suitble to industrialized production.
Invention content
Goal of the invention:In view of the problems of the existing technology, the present invention provides a kind of biology conjunction of ticagrelor intermediate
At method, this method has many advantages, such as synthetic yield height, good product purity.
The present invention also provides a kind of ticagrelor midbody compound (1), the ticagrelor midbody compound (1) be for
Ge Ruiluo provides new raw material.
Technical solution:To achieve the goals above, a kind of biosynthesis side of ticagrelor intermediate as described herein
First compound (3) is made in the oxidized reaction of compound (2) by method;The compound (3) protects being obtained by the reaction through vicinal diols
Close object (4);Compound (5) is made through addition reaction with ethylene oxide in the compound (4);The compound (5) turns through biology
Ticagrelor midbody compound (1) is made in the effect of changing, and reaction equation is as follows:
Wherein, the solvent of the oxidation reaction of compound (3) is made selected from no water beetle in the oxidized reaction of the compound (2)
Alcohol, absolute ethyl alcohol, anhydrous tertiary butanol, anhydrous isopropyl alcohol, anhydrous sec-butyl alcohol, anhydrous THF, anhydrous ether, dry toluene, anhydrous two
One or more of toluene, anhydrous methylene chloride, anhydrous 2- methyltetrahydrofurans and anhydrous TBME, the oxidation reaction it is anti-
It is 20 DEG C~60 DEG C to answer temperature.
Wherein, the solvent that compound (4) is obtained by the reaction through vicinal diols protection for the compound (3) is anhydrous propanone, nothing
It is water tetrahydrofuran, anhydrous ether, anhydrous methyl tertbutyl ether, anhydrous methylene chloride, dry toluene, anhydrous tertbutyl ether, anhydrous
The reaction temperature of one or more of 2- methyltetrahydrofurans, the protection reaction is 20 DEG C~60 DEG C.
Wherein, the solvent that the addition reaction of compound (5) is made with ethylene oxide through addition reaction for the compound (4) is
Anhydrous tetrahydro furan, anhydrous ether, anhydrous methyl tertbutyl ether, anhydrous methylene chloride, dry toluene, anhydrous tertbutyl ether, nothing
One or more of water 2- methyltetrahydrofurans;The temperature of reaction is 0 DEG C~30 DEG C;The reagent of reaction is selected from copper chloride, chlorine
Change cuprous, copper bromide, cuprous bromide, zinc chloride, alchlor, ferric trichloride, trifluoromethayl sulfonic acid ytterbium, titanium tetrachloride and chlorination
One or more of silver.
Wherein, the biology conversion of ticagrelor midbody compound (1) is made through biological transformation for the compound (5)
Enzyme is its initial body or the orthomutation body of the biology converting Enzyme;The amino acid sequence of the biology converting Enzyme is SEQ ID
Shown in NO.1;
SEQ ID NO.1:MAFSADTSEI VYTHDTGLDY ITYSDYELDP ANPLAGGAAW IEGAFVPPSE
ARISIFDQGY LHSDVTYTVF HVWNGNAFRL DDHIERLFSN AESMRIIPPL TQDEVKEIAL ELVAKTELRE
AFVSVSITRG YSSTPGERDI TKHRPQVYMY AVPYQWIVPF DRIRDGVHAM VAQSVRRTPR SSIDPQVKNF
QWGDLIRAVQ ETHDRGFEAP LLLDGDGLLA EGSGFNVVVI KDGVVRSPGR AALPGITRKT VLEIAESLGH
EAILADITLA ELLDADEVLG CTTAGGVWPF VSVDGNPISD GVPGPVTQSI IRRYWELNVE SSSLLTPVQY;
The orthomutation body is T68V, N76L, the one or several kinds in L213E and V302M.Wherein T68V is mother
The T that body is 68 becomes V, other are equivalent.
Wherein, the reaction dissolvent of ticagrelor midbody compound (1) is made through biological transformation for the compound (5)
Selected from water/dimethyl sub-maple, water/methanol, water/ethyl alcohol, water/isopropanol, water/acetone, water/dimethyl sub-maple/first alcohol and water/bis-
One or several kinds in methyl Asia maple/acetone.
Further, the reaction of ticagrelor midbody compound (1) is made through biological transformation for the compound (5)
In further include ammonia source, one or several kinds of the ammonia source in isopropylamine, triethylamine, propylamine, ethamine and butylamine are a concentration of
0.2-1M。
Compound in the reaction of ticagrelor midbody compound (1) is made through biological transformation in the compound (5)
(5) mass concentration is 2-200g/L, and reaction temperature is 22-45 DEG C, and reaction pH is 7.5-8.5.
Preferably, the reaction temperature is 22-25 DEG C, reaction pH is 8.0.
Compound in the reaction of ticagrelor midbody compound (1) is made through biological transformation in the compound (5)
(5) and the mass concentration ratio of biological converting Enzyme is 1:1~70:1.
The synthesized ticagrelor midbody compound of the biological synthesis method of ticagrelor intermediate of the present invention
(1), structural formula is:
Advantageous effect:Compared with prior art, the invention has the advantages that:It is auspicious for lattice that the present invention provides a kind of synthesis
The biological method of Lip river intermediate, this method have synthetic yield height, good product purity, raw material is cheap and easy to get and is suitable for industry
The advantages that metaplasia is produced, while synthesized ticagrelor intermediate provides new intermediate feed for ticagrelor preparation.
Specific implementation mode
The invention will be further described with reference to embodiments.
The method of the detection purity of ticagrelor intermediate HPLC of the present invention:
Test apparatus:1100 high performance liquid chromatographs of Agilent (DAD detectors).
Chromatographic condition:With OB-H (4.6 × 250mm, 5 μm) for chromatographic column, flow velocity:0.5ml/min.
Mobile phase A:Isopropanol;Mobile phase B:Normal heptane
According to the form below carries out linear gradient elution:
| Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 1 | 99 |
| 30 | 5 | 95 |
| 50 | 25 | 75 |
| 60 | 45 | 55 |
Ultraviolet detection wavelength:210nm.
Embodiment 1
The preparation of compound (3)
Under the conditions of 30 DEG C, 980g (10mol) compound (2) is added into 50L reaction kettles in 20L anhydrous tertiary butanols,
N-methylmorpholine N- oxides (NMO) 2.6kg (22mol) is added, OsO is eventually adding4127g (0.5mol) TLC monitoring is anti-
After answering (about 15 hours), niter cake 1.8kg is added, stirs 30 minutes, room temperature is down to after solvent evaporated, with quality point
The aqueous sulfuric acid of number 50% adjusts pH to 1 or so, filtering, and filter cake 10L water washings dry to obtain compound (3) 1.21kg
(9.2mol), yield 92%, HPLC detect purity:97.3%.
1H NMR(400 MHz,DMSO-d6)δ4.35(m,1H),4.18–4.10(m,1H),3.86(m,1H),2.33(dd,
J=19.0,7.0Hz, 1H), 1.96 (dd, J=19.0,7.0Hz, 1H)
ESI+[M+H]+=133.
The preparation of compound (4)
Under the conditions of 25 DEG C, 1.19kg (9.0mol) compound (3) is added into 50L reaction kettles in 18L anhydrous propanones, first
2,2-dimethoxypropane 1.03kg (9.9mol) is added, adds p-methyl benzenesulfonic acid 78g (0.45mol), TLC monitoring reaction knots
After beam (about 5 hours), 15L dichloromethane extraction (2 times) is added, merges organic phase, is concentrated under reduced pressure to give compound (4) crude product
It is directly used in the next step.
The preparation of compound (5)
Under the conditions of 25 DEG C, above compound (4) crude product (9.0mol) is added into 50L reaction kettles in the anhydrous tetrahydrochysenes of 18L
In furans, trifluoromethayl sulfonic acid ytterbium hydrate 6.1kg (9.9mol) is first added, is slow added into ethylene oxide 416g
(9.45mol), TLC are monitored after reaction (about 4 hours), and 5% aqueous ammonium chloride solution 15L of mass fraction is added, heats up, point
Liquid, water phase are extracted with 10L dichloromethane, are merged organic phase, compound (5) crude product are concentrated under reduced pressure to obtain, crude product is through ethyl acetate/stone
Oily ether recrystallizes to obtain highly finished product 1.72kg (7.95mol), and yield is 88.3% (2 step), and HPLC detects purity:98.7%.
1H NMR(400MHz,DMSO-d6) δ 4.95 (t, J=7.0Hz, 1H), 4.66 (d, J=6.9Hz, 1H), 4.38 (m,
1H), 3.52 (m, 1H), 3.46-3.34 (m, 2H), 3.01 (m, 1H), 2.33 (dd, J=19.0,7.0Hz, 1H), 1.97 (dd, J
=19.0,7.0Hz, 1H), 1.22 (s, 3H), 1.17 (s, 3H)
ESI+[M+H]+=217.
The preparation of compound (1)
Under the conditions of 25 DEG C, reaction dissolvent is added into reaction kettle, ammonia source is then added, with salt acid for adjusting pH to 8.0, then
Be added PLP (phosphopyridoxal pyridoxal phosphate) and biology converting Enzyme (amino acid of T68V, N76L, L213E, V302M, 4 positions together by
Substitution), it is slowly stirred to whole dissolvings, compound (5) is then added and reacts afterwards 16 hours, uses salt acid for adjusting pH after reaction
To 2.0, isopropyl acetate extraction is added, leaves water phase, adjusts pH to 12.0 with sodium hydrate aqueous solution, isopropyl acetate is added
Extraction, by isopropyl acetate through compound (1) is concentrated under reduced pressure to obtain.Wherein reaction dissolvent is water and Dimethyl Asian Maple, the two volume ratio
It is 1:1.Ammonia source is isopropylamine and triethylamine, and the molar ratio of a concentration of 0.5M, the two are 1:1.What wherein compound (5) was added is first
A concentration of 100g/L of prothyl amount.The mass concentration ratio of compound (5) and biological converting Enzyme (T68V, N76L, L213E, V302M) is
35:1, PLP is 0.1 times of equivalent of compound (5), and mass concentration is in 10g/L.
Gained intermediate is detected by preceding method, the mass yield of compound 1 is that 97%, HPLC detects purity:
99.92%.
1H NMR(400MHz,DMSO-d6) δ 4.04 (t, J=7.0Hz, 1H), 3.75 (q, J=7.0Hz, 1H), 3.63-
3.44(m,2H),3.43–3.16(m,2H),3.14–2.88(m,3H),1.89(m,2H),1.78(br,2H),1.34(s,3H),
1.33–1.24(s,3H).
ESI+[M+H]+=218.
Embodiment 2
According to the biological synthesis method of embodiment 1, the difference is that:Reaction dissolvent replaces with nothing in prepared by compound 3
Water-ethanol, temperature are 20 DEG C.Compound (3), yield 91.5%, HPLC detect purity:97%.
Reaction dissolvent replaces with anhydrous tetrahydro furan in prepared by compound 4, and temperature is 20 DEG C.
Reaction dissolvent replaces with anhydrous ether in the preparation of compound 5, and reaction reagent replaces with copper chloride, the temperature of reaction
It it is 0 DEG C, compound (5) crude product, yield is 87.5% (2 step), and HPLC detects purity:97.8%.
Reaction dissolvent replaces with water and methanol in the preparation of compound 1, and the two volume ratio is 1:1.Ammonia source replaces with ethamine,
A concentration of 0.2M, pH are adjusted to 7.5.The mass concentration of compound (5) is 2g/L.Compound (5) and biological converting Enzyme biology conversion
The mass concentration ratio of enzyme (amino acid of T68V, 1 position are substituted together) is 1:1, reaction temperature is 22 DEG C, and reaction pH is
7.5.Compound (1) mass yield is that 96%, HPLC detects purity:99.8%.
Embodiment 3
According to the biological synthesis method of embodiment 1, the difference is that:Reaction dissolvent replaces with nothing in prepared by compound 3
Water isopropanol, anhydrous sec-butyl alcohol, volume ratio 1:1, temperature is 60 DEG C.Compound (3), yield 92.5%, HPLC detections are pure
Degree:97.8%.
Reaction dissolvent replaces with anhydrous methylene chloride, dry toluene, volume ratio 1 in prepared by compound 4:1, temperature 60
℃。
Reaction dissolvent replaces with anhydrous methyl tertbutyl ether, anhydrous methylene chloride, volume ratio 1 in the preparation of compound 5:
1, reaction reagent replaces with stannous chloride and copper bromide, molar ratio 1:1, the temperature of reaction is 30 DEG C, compound (5) crude product,
Yield is 89% (2 step), and HPLC detects purity:99%.
Reaction dissolvent replaces with water and ethyl alcohol in the preparation of compound 1, and the two volume ratio is 1:1.Ammonia source replaces with three second
The molar ratio of amine, propylamine, a concentration of 1M, the two is 1:1, pH is adjusted to 8.5.The mass concentration of compound (5) is 200g/L.Chemical combination
Object (5) and the mass concentration ratio of biological converting Enzyme (amino acid of T68V, N76L, L213E, 3 positions is substituted together) are 70:
1, reaction temperature is 45 DEG C, and reaction pH is 8.5.Compound (1) mass yield is that 97%, HPLC detects purity:99.98%.
Embodiment 4
According to the biological synthesis method of embodiment 1, the difference is that:Reaction dissolvent replaces with nothing in prepared by compound 3
Water methanol, temperature are 40 DEG C.Compound (3), yield 92.4%, HPLC detect purity:98%.
Reaction dissolvent replaces with anhydrous methyl tertbutyl ether in prepared by compound 4, and temperature is 40 DEG C.
Reaction dissolvent replaces with anhydrous methyl tertbutyl ether in the preparation of compound 5, and reaction reagent replaces with ferric trichloride,
The temperature of reaction is 15 DEG C, compound (5) crude product, and yield is 89.2% (2 step), and HPLC detects purity:99.3%.
Reaction dissolvent replaces with water and acetone in the preparation of compound 1, and the two volume ratio is 1:1.Ammonia source replaces with propylamine,
A concentration of 0.6M.The mass concentration of compound (5) is 100g/L.Compound (5) and biological converting Enzyme (L213E, V302M, 2
The amino acid of position is substituted together) mass concentration ratio be 35:1, reaction temperature is 35 DEG C, and reaction pH is 8.0.Compound
(1) mass yield is that 96.6%, HPLC detects purity:99.95%.
Sequence table
<110>Huaiyingong College
<120>A kind of biological synthesis method and its intermediate of ticagrelor intermediate
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 330
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 1
Met Ala Phe Ser Ala Asp Thr Ser Glu Ile Val Tyr Thr His Asp Thr
1 5 10 15
Gly Leu Asp Tyr Ile Thr Tyr Ser Asp Tyr Glu Leu Asp Pro Ala Asn
20 25 30
Pro Leu Ala Gly Gly Ala Ala Trp Ile Glu Gly Ala Phe Val Pro Pro
35 40 45
Ser Glu Ala Arg Ile Ser Ile Phe Asp Gln Gly Tyr Leu His Ser Asp
50 55 60
Val Thr Tyr Thr Val Phe His Val Trp Asn Gly Asn Ala Phe Arg Leu
65 70 75 80
Asp Asp His Ile Glu Arg Leu Phe Ser Asn Ala Glu Ser Met Arg Ile
85 90 95
Ile Pro Pro Leu Thr Gln Asp Glu Val Lys Glu Ile Ala Leu Glu Leu
100 105 110
Val Ala Lys Thr Glu Leu Arg Glu Ala Phe Val Ser Val Ser Ile Thr
115 120 125
Arg Gly Tyr Ser Ser Thr Pro Gly Glu Arg Asp Ile Thr Lys His Arg
130 135 140
Pro Gln Val Tyr Met Tyr Ala Val Pro Tyr Gln Trp Ile Val Pro Phe
145 150 155 160
Asp Arg Ile Arg Asp Gly Val His Ala Met Val Ala Gln Ser Val Arg
165 170 175
Arg Thr Pro Arg Ser Ser Ile Asp Pro Gln Val Lys Asn Phe Gln Trp
180 185 190
Gly Asp Leu Ile Arg Ala Val Gln Glu Thr His Asp Arg Gly Phe Glu
195 200 205
Ala Pro Leu Leu Leu Asp Gly Asp Gly Leu Leu Ala Glu Gly Ser Gly
210 215 220
Phe Asn Val Val Val Ile Lys Asp Gly Val Val Arg Ser Pro Gly Arg
225 230 235 240
Ala Ala Leu Pro Gly Ile Thr Arg Lys Thr Val Leu Glu Ile Ala Glu
245 250 255
Ser Leu Gly His Glu Ala Ile Leu Ala Asp Ile Thr Leu Ala Glu Leu
260 265 270
Leu Asp Ala Asp Glu Val Leu Gly Cys Thr Thr Ala Gly Gly Val Trp
275 280 285
Pro Phe Val Ser Val Asp Gly Asn Pro Ile Ser Asp Gly Val Pro Gly
290 295 300
Pro Val Thr Gln Ser Ile Ile Arg Arg Tyr Trp Glu Leu Asn Val Glu
305 310 315 320
Ser Ser Ser Leu Leu Thr Pro Val Gln Tyr
325 330
Claims (10)
1. a kind of biological synthesis method of ticagrelor intermediate, which is characterized in that first the oxidized reaction of compound (2) is made
Compound (3);Compound (4) is obtained by the reaction through vicinal diols protection in the compound (3);The compound (4) and epoxy second
Compound (5) is made through addition reaction in alkane;Ticagrelor midbody compound is made through biological transformation in the compound (5)
(1), reaction equation is as follows:
2. the biological synthesis method of ticagrelor intermediate according to claim 1, which is characterized in that the compound
(2) solvent of the oxidation reaction of compound (3) is made selected from absolute methanol, absolute ethyl alcohol, anhydrous tertiary butanol, nothing in oxidized reaction
Water isopropanol, anhydrous sec-butyl alcohol, anhydrous THF, anhydrous ether, dry toluene, anhydrous dimethyl benzene, anhydrous methylene chloride, anhydrous 2-
The reaction temperature of one or more of methyltetrahydrofuran and anhydrous TBME, the oxidation reaction is 20 DEG C~60 DEG C.
3. the biological synthesis method of ticagrelor intermediate according to claim 1, which is characterized in that the compound
(3) solvent that compound (4) is obtained by the reaction through vicinal diols protection is anhydrous propanone, anhydrous tetrahydro furan, anhydrous ether, anhydrous
Methyl tertiary butyl ether(MTBE), anhydrous methylene chloride, dry toluene, anhydrous tertbutyl ether, one kind in anhydrous 2- methyltetrahydrofurans or
Several, the reaction temperature of the protection reaction is 20 DEG C~60 DEG C.
4. the biological synthesis method of ticagrelor intermediate according to claim 1, which is characterized in that the compound
(4) with ethylene oxide be made through addition reaction compound (5) addition reaction solvent be anhydrous tetrahydro furan, anhydrous ether,
One in anhydrous methyl tertbutyl ether, anhydrous methylene chloride, dry toluene, anhydrous tertbutyl ether, anhydrous 2- methyltetrahydrofurans
Kind is several;The temperature of reaction is 0 DEG C~30 DEG C;The reagent of reaction be selected from copper chloride, stannous chloride, copper bromide, cuprous bromide,
Zinc chloride, alchlor, ferric trichloride, trifluoromethayl sulfonic acid ytterbium, one or more of titanium tetrachloride and silver chlorate.
5. the biological synthesis method of ticagrelor intermediate according to claim 1, which is characterized in that the compound
(5) the biological converting Enzyme that ticagrelor midbody compound (1) is made through biological transformation is its initial body or the biology
The orthomutation body of converting Enzyme;The amino acid sequence of the biology converting Enzyme is shown in SEQ ID NO.1;The orthomutation body
For T68V, N76L, the one or several kinds in L213E and V302M.
6. the biological synthesis method of ticagrelor intermediate according to claim 1, which is characterized in that the feature exists
In the reaction dissolvent that ticagrelor midbody compound (1) is made through biological transformation for the compound (5) is selected from water/bis-
Methyl Asia maple, water/methanol, water/ethyl alcohol, water/isopropanol, water/acetone, water/dimethyl sub-maple/first alcohol and water/dimethyl sub-maple/
One or several kinds in acetone.
7. the biological synthesis method of ticagrelor intermediate according to claim 1, which is characterized in that the feature exists
In, it further includes ammonia source that the compound (5), which is made through biological transformation in the reaction of ticagrelor midbody compound (1),
One or several kinds of the ammonia source in isopropylamine, triethylamine, propylamine, ethamine and butylamine, a concentration of 0.2-1M.
8. the biological synthesis method of the ticagrelor intermediate according to claim 1-7, which is characterized in that the compound
(5) mass concentration that compound (5) in the reaction of ticagrelor midbody compound (1) is made through biological transformation is 2-
200g/L, reaction temperature are 22-45 DEG C, and reaction pH is 7.5-8.5.
9. the biological synthesis method of ticagrelor intermediate according to claim 5, which is characterized in that the compound
(5) matter of compound (5) and biological converting Enzyme in the reaction of ticagrelor midbody compound (1) is made through biological transformation
It is 1 to measure concentration ratio:1~70:1.
10. among a kind of synthesized ticagrelor of the biological synthesis method of ticagrelor intermediate as described in claim 1
Body compound (1), structural formula are:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810409842.0A CN108689984B (en) | 2018-05-02 | 2018-05-02 | A kind of biological synthesis method and its intermediate of ticagrelor intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810409842.0A CN108689984B (en) | 2018-05-02 | 2018-05-02 | A kind of biological synthesis method and its intermediate of ticagrelor intermediate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108689984A true CN108689984A (en) | 2018-10-23 |
| CN108689984B CN108689984B (en) | 2019-09-20 |
Family
ID=63845153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810409842.0A Active CN108689984B (en) | 2018-05-02 | 2018-05-02 | A kind of biological synthesis method and its intermediate of ticagrelor intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108689984B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115785058A (en) * | 2022-12-09 | 2023-03-14 | 广州康瑞泰药业有限公司 | Method for synthesizing ticagrelor five-membered ring intermediate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001092263A1 (en) * | 2000-06-02 | 2001-12-06 | Astrazeneca Ab | Novel triazolo pyrimidine compounds |
| CN103539773A (en) * | 2013-09-25 | 2014-01-29 | 开原亨泰制药股份有限公司 | Method for preparing ticagrelor key intermediate |
| CN105073983A (en) * | 2013-02-28 | 2015-11-18 | 默沙东公司 | Immobilized transaminases and process for making and using immobilized transaminase |
-
2018
- 2018-05-02 CN CN201810409842.0A patent/CN108689984B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001092263A1 (en) * | 2000-06-02 | 2001-12-06 | Astrazeneca Ab | Novel triazolo pyrimidine compounds |
| CN105073983A (en) * | 2013-02-28 | 2015-11-18 | 默沙东公司 | Immobilized transaminases and process for making and using immobilized transaminase |
| CN103539773A (en) * | 2013-09-25 | 2014-01-29 | 开原亨泰制药股份有限公司 | Method for preparing ticagrelor key intermediate |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115785058A (en) * | 2022-12-09 | 2023-03-14 | 广州康瑞泰药业有限公司 | Method for synthesizing ticagrelor five-membered ring intermediate |
| CN115785058B (en) * | 2022-12-09 | 2024-05-03 | 广州康瑞泰药业有限公司 | Method for synthesizing ticagrelor five-membered ring intermediate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108689984B (en) | 2019-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3064214A1 (en) | Separation and purification method for vancomycin hydrochloride of high purity | |
| CN101928309A (en) | 3,2',6'-tri-N-acetyl gentamicin C1asynthesis method | |
| KR102308524B1 (en) | Process for the preparation of xanthohumol | |
| CN108689984B (en) | A kind of biological synthesis method and its intermediate of ticagrelor intermediate | |
| CN105254721B (en) | Purification and salt conversion method of micafungin | |
| CN105503842A (en) | Method for preparing nebivolol hydrochloride epoxy intermediate 6-fluoro-2-epoxy ethyl chroman | |
| CN103864813B (en) | Synthetic methods of hexahydrofuro[2,3-b]furan-3-ol and enantiomer thereof | |
| CN105039450B (en) | A kind of synthetic method of Chinese mugwort fluconazole intermediate | |
| CN106905182A (en) | The synthetic method and its intermediate of a kind of ticagrelor intermediate | |
| CN106854158B (en) | A kind of synthetic method and its intermediate of ticagrelor intermediate | |
| CN113337553B (en) | Herbicidin biosynthesis gene cluster and application thereof | |
| Bujaranipalli et al. | First stereoselective total synthesis of paecilomycin G | |
| CN114426538B (en) | Berberine canagliflozin derivative and preparation method and application thereof | |
| CN101787003A (en) | Preparation method of 5,6-epoxy-5,6-dihydro-beta-ionol | |
| Han et al. | New derivatives of nonactic and homononactic acids from Bacillus pumilus derived from Breynia fruticosa | |
| CN104262441B (en) | The method of dichloro fluorine compound ethyl ester one-step synthesis halometasone | |
| CN107089957B (en) | A kind of preparation method of 4H-5- (1- hydroxyl -1- Methylethyl) -2- methyl -2- furans ethyl alcohol | |
| CN112920233A (en) | Synthetic method of emamectin benzoate with improved processability | |
| AU2016362540B2 (en) | Antibiotic FIIRV 104/18 complex and the isolated individual factors thereof | |
| CN103333129A (en) | Method for preparing 4-amino-6-tertiary butyl-3-methylmercapto-1,2,4-triazine-5(4H)-ketone | |
| CN103554061A (en) | Preparation method of 5-(3, 3-dimethyloxirane)-3-methyl-2-pentene-1-alcohol | |
| CN103333130A (en) | Preparation method of 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazine 5 (4H)-ketone | |
| CN107129475B (en) | A kind of preparation method of furan type linalool oxide | |
| CN103382208B (en) | The preparation method of Arglabin | |
| CN109970620A (en) | A method of preparing onglyza intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |